Exscientia stock.

The latest Exscientia stock prices, stock quotes, news, and EXAI history to help you invest and trade smarter.Exscientia PLC ( EXAI) has gained Monday morning, with the stock adding 3.08% in pre-market trading to 6.36. EXAI's short-term technical score of 56 indicates …Exscientia has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Valneva has a beta of 2.48, indicating that its stock price is 148% more volatile than the S&P 500.Dec 1, 2023 · 2012. 481. Andrew Hopkins. https://www.exscientia.ai. Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and ...

What is Exscientia's Market Cap? ( NASDAQ: EXAI) Exscientia 's market cap is $727.15M, as of Nov 24, 2023. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Exscientia 's market cap is calculated by multiplying EXAI 's current stock price of $5.84 by EXAI 's total …

Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI …If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.

Last but not least, Exscientia's AI-driven drug discovery platform is able to anticipate the effectiveness of cancer therapy in the clinic, while also matching the drug with the most relevant patient group. AbCellera Biologics Inc (NASDAQ: ABCL) AbCellera is a Vancouver-based biotech company, which develops antibody therapeutics using AI.In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from ...Shares of Exscientia PLC Sponsored ADR (EXAI) have gained 7.6% over the past four weeks to close the last trading session at $5.40, but there could still be a solid upside left in the stock if ...May 18, 2023 · Exscientia's AI-driven drug discovery platform positioned the company at the forefront of precision medicine. Read why EXAI stock is a Buy.

Another stock in the Medical sector, Exscientia PLC Sponsored ADR (EXAI), has outperformed the sector so far this year. The stock's year-to-date return is 9.6%.

AUTL. Autolus Therapeutics PLC. 4.80. UNCH. UNCH. Get Exscientia PLC (EXAI:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

A. While ratings are subjective and will change, the latest Exscientia ( EXAI) rating was a maintained with a price target of $12.00 to $10.00. The current price Exscientia ( EXAI) is trading at ...One reason for this week's share growth was the company's first-quarter earnings report. Its reported revenue of $7.1 million was down 17.4% year over year, and its net loss was $46.6 million, 143 ...This free interactive report on Exscientia's balance sheet strength is a great place to start, if you want to investigate the stock further.. A Different Perspective. Exscientia shareholders are ...Exscientia Stock Up 2.1 %. NASDAQ:EXAI opened at $5.40 on Wednesday. The firm’s 50 day simple moving average is $5.70 and its 200 day simple moving average is $6.18. The company has a debt-to ...Exscientia’s market value soared as shares of the artificial intelligence (AI) p harmaceutical-technology (pharmatech) company debuted on the stock market. Shares of the Oxford, England company rose more than 30% following Exscientia’s upsized initial public offering (IPO).View Exscientia PLC Sponsored ADR EXAI investment & stock information. Get the latest Exscientia PLC Sponsored ADR EXAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Revenue: Revenue for the three and nine months ended September 30, 2023 was $10.8 million and $21.6 million respectively, compared to $7.7 million and $24.9 million for the three and nine months ...Description. Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe and efficacious compounds for clinical ... OXFORD, England, March 14, 2023--Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.How much is Exscientia stock worth today? ( NASDAQ: EXAI) Exscientia currently has 124,511,492 outstanding shares. With Exscientia stock trading at $6.17 per share, the total value of Exscientia stock (market capitalization) is $768.24M. Exscientia stock was originally listed at a price of $27.10 in Oct 1, 2021.

EXS73565. MALT1. * Phase 3 may not be required if Phase 2 is registrational: PKC-theta is in a Phase 1 healthy volunteer study. Does not include Sumitomo Pharma programmes. Our pipeline demonstrates our ability to rapidly translate scientific concepts and patient-centric data into precision-designed therapeutic candidates.

1 окт. 2021 г. ... Company had anticipated proceeds of $287m. The better-than-expected IPO came after Escientia planned to sell 13.1 million ADS for $20-$22 in the ...According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.This came just a few months after Recursion raised $436 million in an upsized IPO in April 2021 (Table 1). Exscientia, a pioneer in applying AI to small-molecule drug design, had a hefty IPO in ...OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor. These compounds have been precision designed to improve the potential for patient …OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor. These compounds have been precision designed to improve the potential for patient …The company also recognized $1.5 million in net foreign exchange losses. Exscientia's stock showed mixed momentum, with a one-year decline of 24.04%, but positive growth over 3, 6, and 9 months.We are a creative, passionate and collaborative organisation dedicated to setting bold new standards in drug discovery and design. If you have the ingenuity, energy and ambition to help us change the world, we would love to hear from you. Open positions. At Exscientia, we combine the power of AI and human creativity to make safer and more ...Currently, the most bullish analyst values Exscientia at UK£13.35 per share, while the most bearish prices it at UK£9.43. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Exscientia (NASDAQ:EXAI) has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $14.0 versus the current price of Exscientia at $6.1 ...

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom. EXAI - Exscientia Plc ADR - Stock screener for investors and traders, financial ...

Stock analysis for Exscientia Plc (EXAI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.OXFORD, England & HOUSTON, Texas--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD …Find real-time EXAI - Exscientia PLC stock quotes, company profile, news and forecasts from CNN Business.First AI platform clinically validated to improve treatment outcomes in prospective study. Exscientia, a clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine. The combination expands Exscientia’s translational capabilities by enabling …EXAI Exscientia plc Stock Price & Overview $6.12 0.02 ( +0.33%) 2:54 PM 12/01/23 NASDAQ | $USD | Realtime Summary Ratings Financials Earnings Dividends …PARIS, OXFORD, and BOSTON – January 7, 2022 – Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilizing actual patient samples. …At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.We would like to show you a description here but the site won’t allow us.OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in Orlando, FL. “We’re excited to further validate Exscientia’s end-to-end approach of integrating outstanding …Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI …Exscientia’s market value soared as shares of the artificial intelligence (AI) p harmaceutical-technology (pharmatech) company debuted on the stock market. Shares of the Oxford, England company rose more than 30% following Exscientia’s upsized initial public offering (IPO).

Portfolio news - Exscientia raises US$26 million in Series B funding round and announces AI drug discovery collaboration with Roche worth up to CHF 67 million ... This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider …Exscientia Limited stock news. This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash. By directing users to the below third-party websites, Stash is not suggesting any endorsement, relationship, affiliation with any such websites. ...According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Dec 1, 2023 · Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar? finance.yahoo.com - October 12 at 9:54 AM: Exscientia plc (NASDAQ:EXAI) most popular amongst individual investors who own 58% of the shares, institutions hold 27% finance.yahoo.com - October 11 at 8:42 AM Instagram:https://instagram. micro currency tradingrare mexican coinsoverall nikestratasys ltd stock Mar 7, 2023 · Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 5.38% so far this month. During the month of March, Exscientia PLC (ADR)’s stock price has reached a high of $7.11 and a low of $6.02. Over the last year, Exscientia PLC (ADR) has hit prices as high as $17.66 and as low as $4.09. Year to date, Exscientia ... how to read a candlestick chartpcgome OXFORD, England & HOUSTON, Texas--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD …TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.com scootrade First AI platform clinically validated to improve treatment outcomes in prospective study. Exscientia, a clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine. The combination expands Exscientia’s translational capabilities by enabling …EXS73565. MALT1. * Phase 3 may not be required if Phase 2 is registrational: PKC-theta is in a Phase 1 healthy volunteer study. Does not include Sumitomo Pharma programmes. Our pipeline demonstrates our ability to rapidly translate scientific concepts and patient-centric data into precision-designed therapeutic candidates.